{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05554406",
            "orgStudyIdInfo": {
                "id": "NCI-2022-07535"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2022-07535",
                    "type": "REGISTRY",
                    "domain": "CTRP (Clinical Trial Reporting Program)"
                },
                {
                    "id": "MM1YA-S01",
                    "type": "OTHER",
                    "domain": "SWOG"
                },
                {
                    "id": "MM1YA-S01",
                    "type": "OTHER",
                    "domain": "CTEP"
                },
                {
                    "id": "U10CA180888",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/U10CA180888"
                }
            ],
            "organization": {
                "fullName": "National Cancer Institute (NCI)",
                "class": "NIH"
            },
            "briefTitle": "Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)",
            "officialTitle": "A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger With High-Risk (Adverse) Acute Myeloid Leukemia; A MYELOMATCH Clinical Trial",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "testing-the-effects-of-novel-therapeutics-for-newly-diagnosed-untreated-patients-with-high-risk-acute-myeloid-leukemia-a-myelomatch-treatment-trial"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2025-02-10",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-03-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-03-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-09-22",
            "studyFirstSubmitQcDate": "2022-09-22",
            "studyFirstPostDateStruct": {
                "date": "2022-09-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "National Cancer Institute (NCI)",
                "class": "NIH"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. \"High-risk\" refers to traits that have been known to make the AML harder to treat. Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a class of medications called anthracyclines. It also works by slowing or stopping the growth of cancer cells in the body. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment regimens may work better in getting rid of more AML compared to the standard approach of cytarabine and daunorubicin.",
            "detailedDescription": "PRIMARY OBJECTIVE:\n\nI. To compare measurable residual disease (MRD) negative complete remission (CR) rates between each of the experimental regimens and cytarabine + daunorubicin (7+3).\n\nSECONDARY OBJECTIVES:\n\nI. To estimate the frequency and severity of toxicities with each of the regimens.\n\nII. To estimate complete remission (CR) rates, complete remission with incomplete count recovery (CRi, with and without MRD) rates, event-free survival (EFS), time to relapse, relapse-free survival (RFS), and overall survival (OS) with each of the regimens.\n\nIII. To describe and compare MRD negative CR rates by genomic subgroups within and across randomized arms.\n\nBAKING OBJECTIVE:\n\nI. To bank specimens for future correlative studies.\n\nOUTLINE: Patients are randomized to 1 of 5 arms.\n\nARM I: Patients receive cytarabine intravenously (IV) continuously on days 1-7 and daunorubicin IV on days 1-3 per standard approach of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1-2. Patients undergo echocardiography (ECHO) or multigated acquisition (MUGA) scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.\n\nARM II: Patients receive cytarabine IV continuously on days 2-8 and daunorubicin IV on days 2-4 with venetoclax orally (PO) on days 1-11 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 2-6 and daunorubicin IV on days 2-3 with venetoclax PO on days 1-8. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.\n\nARM III: Patients receive azacitidine subcutaneously (SC) or IV on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.\n\nARM IV: Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.\n\nARM V: Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 and venetoclax PO on days 1-14 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3 and venetoclax PO on days 1-7. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.\n\nAfter completion of study treatment, patients follow up every month for first year, every 2 months for the second year, every 3 months for the third year and every 6 months to year 5."
        },
        "conditionsModule": {
            "conditions": [
                "Acute Myeloid Leukemia",
                "Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm",
                "Acute Myeloid Leukemia Post Cytotoxic Therapy",
                "Acute Myeloid Leukemia, Myelodysplasia-Related"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 335,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm I (cytarabine, daunorubicin)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3 per standard approach of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1-2. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.",
                    "interventionNames": [
                        "Procedure: Biospecimen Collection",
                        "Procedure: Bone Marrow Aspiration",
                        "Drug: Cytarabine",
                        "Drug: Daunorubicin Hydrochloride",
                        "Procedure: Echocardiography",
                        "Procedure: Multigated Acquisition Scan"
                    ]
                },
                {
                    "label": "Arm II (cytarabine, daunorubicin, venetoclax)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients receive cytarabine IV continuously on days 2-8 and daunorubicin IV on days 2-4 with venetoclax PO on days 1-11 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 2-6 and daunorubicin IV on days 2-3 with venetoclax PO on days 1-8. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.",
                    "interventionNames": [
                        "Procedure: Biospecimen Collection",
                        "Procedure: Bone Marrow Aspiration",
                        "Drug: Cytarabine",
                        "Drug: Daunorubicin Hydrochloride",
                        "Procedure: Echocardiography",
                        "Procedure: Multigated Acquisition Scan",
                        "Drug: Venetoclax"
                    ]
                },
                {
                    "label": "Arm III (azacitidine, venetoclax)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients receive azacitidine SC or IV on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.",
                    "interventionNames": [
                        "Drug: Azacitidine",
                        "Procedure: Biospecimen Collection",
                        "Procedure: Echocardiography",
                        "Procedure: Multigated Acquisition Scan",
                        "Drug: Venetoclax"
                    ]
                },
                {
                    "label": "Arm IV (daunorubicin and cytarabine liposome)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.",
                    "interventionNames": [
                        "Procedure: Biospecimen Collection",
                        "Procedure: Bone Marrow Aspiration",
                        "Procedure: Echocardiography",
                        "Drug: Liposome-encapsulated Daunorubicin-Cytarabine",
                        "Procedure: Multigated Acquisition Scan"
                    ]
                },
                {
                    "label": "Arm V (daunorubicin and cytarabine liposome, venetoclax)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 and venetoclax PO on days 1-14 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3 and venetoclax PO on days 1-7. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.",
                    "interventionNames": [
                        "Procedure: Biospecimen Collection",
                        "Procedure: Bone Marrow Aspiration",
                        "Procedure: Echocardiography",
                        "Drug: Liposome-encapsulated Daunorubicin-Cytarabine",
                        "Procedure: Multigated Acquisition Scan",
                        "Drug: Venetoclax"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Azacitidine",
                    "description": "Given SC or IV",
                    "armGroupLabels": [
                        "Arm III (azacitidine, venetoclax)"
                    ],
                    "otherNames": [
                        "5 AZC",
                        "5-AC",
                        "5-Azacitidine",
                        "5-Azacytidine",
                        "5-AZC",
                        "Azacytidine",
                        "Azacytidine, 5-",
                        "Ladakamycin",
                        "Mylosar",
                        "U-18496",
                        "Vidaza"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Biospecimen Collection",
                    "description": "Undergo collection of blood",
                    "armGroupLabels": [
                        "Arm I (cytarabine, daunorubicin)",
                        "Arm II (cytarabine, daunorubicin, venetoclax)",
                        "Arm III (azacitidine, venetoclax)",
                        "Arm IV (daunorubicin and cytarabine liposome)",
                        "Arm V (daunorubicin and cytarabine liposome, venetoclax)"
                    ],
                    "otherNames": [
                        "Biological Sample Collection",
                        "Biospecimen Collected",
                        "Specimen Collection"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Bone Marrow Aspiration",
                    "description": "Undergo bone marrow aspiration",
                    "armGroupLabels": [
                        "Arm I (cytarabine, daunorubicin)",
                        "Arm II (cytarabine, daunorubicin, venetoclax)",
                        "Arm IV (daunorubicin and cytarabine liposome)",
                        "Arm V (daunorubicin and cytarabine liposome, venetoclax)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cytarabine",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Arm I (cytarabine, daunorubicin)",
                        "Arm II (cytarabine, daunorubicin, venetoclax)"
                    ],
                    "otherNames": [
                        ".beta.-Cytosine arabinoside",
                        "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone",
                        "1-.beta.-D-Arabinofuranosylcytosine",
                        "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone",
                        "1-Beta-D-arabinofuranosylcytosine",
                        "1.beta.-D-Arabinofuranosylcytosine",
                        "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-",
                        "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-",
                        "Alexan",
                        "Ara-C",
                        "ARA-cell",
                        "Arabine",
                        "Arabinofuranosylcytosine",
                        "Arabinosylcytosine",
                        "Aracytidine",
                        "Aracytin",
                        "Aracytine",
                        "Beta-Cytosine Arabinoside",
                        "CHX-3311",
                        "Cytarabinum",
                        "Cytarbel",
                        "Cytosar",
                        "Cytosine Arabinoside",
                        "Cytosine-.beta.-arabinoside",
                        "Cytosine-beta-arabinoside",
                        "Erpalfa",
                        "Starasid",
                        "Tarabine PFS",
                        "U 19920",
                        "U-19920",
                        "Udicil",
                        "WR-28453"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Daunorubicin Hydrochloride",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Arm I (cytarabine, daunorubicin)",
                        "Arm II (cytarabine, daunorubicin, venetoclax)"
                    ],
                    "otherNames": [
                        "Cerubidin",
                        "Cerubidine",
                        "Cloridrato de Daunorubicina",
                        "Daunoblastin",
                        "Daunoblastina",
                        "Daunoblastine",
                        "Daunomycin Hydrochloride",
                        "Daunomycin, hydrochloride",
                        "Daunorubicin.HCl",
                        "Daunorubicini Hydrochloridum",
                        "FI-6339",
                        "Ondena",
                        "RP-13057",
                        "Rubidomycin Hydrochloride",
                        "Rubilem"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Echocardiography",
                    "description": "Undergo ECHO",
                    "armGroupLabels": [
                        "Arm I (cytarabine, daunorubicin)",
                        "Arm II (cytarabine, daunorubicin, venetoclax)",
                        "Arm III (azacitidine, venetoclax)",
                        "Arm IV (daunorubicin and cytarabine liposome)",
                        "Arm V (daunorubicin and cytarabine liposome, venetoclax)"
                    ],
                    "otherNames": [
                        "EC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Liposome-encapsulated Daunorubicin-Cytarabine",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Arm IV (daunorubicin and cytarabine liposome)",
                        "Arm V (daunorubicin and cytarabine liposome, venetoclax)"
                    ],
                    "otherNames": [
                        "CPX 351",
                        "CPX-351",
                        "CPX351",
                        "Cytarabine and Daunorubicin Liposomal",
                        "Cytarabine-Daunorubicin Liposome for Injection",
                        "Daunorubicin and Cytarabine (Liposomal)",
                        "Liposomal AraC-Daunorubicin CPX-351",
                        "Liposomal Cytarabine-Daunorubicin",
                        "Liposome-encapsulated Combination of Daunorubicin and Cytarabine",
                        "Vyxeos"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Multigated Acquisition Scan",
                    "description": "Undergo MUGA",
                    "armGroupLabels": [
                        "Arm I (cytarabine, daunorubicin)",
                        "Arm II (cytarabine, daunorubicin, venetoclax)",
                        "Arm III (azacitidine, venetoclax)",
                        "Arm IV (daunorubicin and cytarabine liposome)",
                        "Arm V (daunorubicin and cytarabine liposome, venetoclax)"
                    ],
                    "otherNames": [
                        "Blood Pool Scan",
                        "Equilibrium Radionuclide Angiography",
                        "Gated Blood Pool Imaging",
                        "Gated Heart Pool Scan",
                        "MUGA",
                        "MUGA Scan",
                        "Multi-Gated Acquisition Scan",
                        "Radionuclide Ventriculogram Scan",
                        "Radionuclide Ventriculography",
                        "RNVG",
                        "SYMA Scanning",
                        "Synchronized Multigated Acquisition Scanning"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Venetoclax",
                    "description": "Given PO",
                    "armGroupLabels": [
                        "Arm II (cytarabine, daunorubicin, venetoclax)",
                        "Arm III (azacitidine, venetoclax)",
                        "Arm V (daunorubicin and cytarabine liposome, venetoclax)"
                    ],
                    "otherNames": [
                        "ABT 199",
                        "ABT-0199",
                        "ABT-199",
                        "ABT199",
                        "GDC 0199",
                        "GDC-0199",
                        "GDC0199",
                        "RG7601",
                        "Venclexta",
                        "Venclyxto"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Minimal residual disease (MRD) response (Arm 1, 2, 4 and 5)",
                    "description": "Will be analyzed using intent-to-treat (ITT) principles.",
                    "timeFrame": "After induction (28 days) or re-induction (56 days)"
                },
                {
                    "measure": "Minimal residual disease (MRD) response (Arm 3)",
                    "description": "Will be analyzed using intent-to-treat (ITT) principles.",
                    "timeFrame": "After two cycles of therapy (56 days)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Early mortality",
                    "description": "Will be assessed by death due to any cause between experimental arms and the 7+3 arm will be reported for each arm every DSMC cycle. Fisher's exact will be used to compare observed rates. A one-sided p-value \\< 0.05 indicating increased early mortality rates in an experimental arm will be a threshold for termination of accrual to an arm due to increased early mortality.",
                    "timeFrame": "On or before day 28"
                },
                {
                    "measure": "Time to count recovery",
                    "description": "Will be reported every DSMC cycle for the 7+3+venetoclax, (daunorubicin and cytarabine) liposome+venetoclax, and 7+3 arms. Median time to count recovery more than 7 days longer on either of the 7+3+venetoclax and (daunorubicin and cytarabine liposome+venetoclax arms compared to the 7+3 arm will be used a threshold to terminate accrual to an arm due to increased toxicity.",
                    "timeFrame": "After cycle 1 and cycle 2"
                },
                {
                    "measure": "Event-free survival (EFS)",
                    "description": "Will be estimated using the Kaplan-Meier method.",
                    "timeFrame": "From randomization to the first of: primary refractory disease; progressive disease; off protocol therapy without complete remission (CR) or CR with incomplete count recovery (CRi); relapse from CR or CRi, or death from any cause, assessed up to 5 years"
                },
                {
                    "measure": "Relapse-free survival (RFS)",
                    "description": "Defined for only patients achieving complete remission (CR), or CR with incomplete hematologic recovery (CRi). Will be estimated using the Kaplan-Meier method.",
                    "timeFrame": "From the date of achievement of a remission until the date of relapse or death from any cause, assessed up to 5 years"
                },
                {
                    "measure": "Overall survival (OS)",
                    "description": "Will be estimated using the Kaplan-Meier method.",
                    "timeFrame": "From day of randomization on study until death from any cause, assessed up to 5 years"
                },
                {
                    "measure": "Time to relapse",
                    "description": "Will be estimated with cumulative incidence curves with death without relapse analyzed a competing event. Response per 2017 European LeukemiaNet (ELN) guidelines will be tabulated and exact 95% confidence intervals will be calculated.",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "MRD negative complete remission (MRDneg CR)",
                    "description": "MRDneg CR rates will be tabulated by genomic subgroups within randomized arms and pooling arms. Rates across arms will be compared using Fisher's exact test. All p-values reported will be nominal.",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "Incidence of adverse events",
                    "description": "Will be analyzed using National Cancer Institute Common Terminology Criteria for Adverse Events version (v) 5.0",
                    "timeFrame": "Up to 5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* STEP 1 REGISTRATION:\n* Participants must have been registered to Master Screening and Re-Assessment Protocol, myeloMATCH MSRP, prior to consenting to this study. Participants must have been assigned to this clinical trial, via MATCHBox, prior to registration to this study.\n\n  * Note: Pre-enrollment/diagnosis labs must have already been performed under the MSRP\n* Participants must have newly diagnosed, untreated acute myeloid leukemia (AML) per World Health Organization (WHO) criteria\n* Participants must have high-risk (adverse) AML per European LeukemiaNet (ELN) 2017 criteria\n* Participants with therapy-related AML (t-AML), or with AML evolving from an antecedent hematologic disorder (such as myeloproliferative neoplasm), or AML with myelodysplasia-related changes (AML-MRC) are eligible\n* Acute promyelocytic leukemia is excluded\n* Participants with favorable or intermediate risk disease are excluded\n* Participants with FLT3 mutations (ITD or TKD) are excluded\n* Participants with t(9;22) translocation are excluded\n* A single dose of intrathecal chemotherapy is allowed prior to study entry\n* Prior anthracycline therapy is allowed but must not exceed a cumulative lifetime dose of 200 mg/m\\^2 daunorubicin or equivalent. Prior hypomethylating agent (HMA) exposure is allowed, as long as not for AML diagnosis\n* Participants must not have received or be currently receiving any prior therapy for acute myeloid leukemia. Hydroxyurea to control the white blood cells (WBC) is allowed prior to registration and initiation of protocol-defined therapy. All trans retinoic acid (ATRA) given until a diagnosis of acute promyelocytic leukemia is ruled out is also allowed.\n* Participants must not be receiving or planning to receive any other investigational agents before completing protocol therapy\n* Participants must be between 18 and 59 years of age\n* Participants must have Zubrod performance status =\\< 3 as determined by a history and physical (H\\&P) completed within 14 days prior to registration\n* Participants must have a complete medical history and physical exam within 7 days prior to registration\n* Participants must be able to swallow and retain oral medications and have no known gastrointestinal disorders likely to interfere with absorption of oral medications\n* Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at time of registration and have undetectable HIV viral load within 6 months prior to registration\n* Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load within 28 days prior to registration and be on suppressive therapy, if indicated\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with active HCV infection who are currently on treatment must have an undetectable HCV viral load within 28 days prior to registration\n* The following tests must be performed within 14 days prior to registration to establish baseline values:\n\n  * Complete blood count (CBC)/differential/platelets\n  * Total bilirubin\n  * Lactate dehydrogenase (LDH)\n  * Albumin\n  * Glucose\n  * Fibrinogen\n* Participants must have adequate kidney function as evidenced by creatinine clearance \\>= 30mL/min (by Cockcroft Gault) within 28 days prior to registration\n* Participants must have adequate liver function as evidenced by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\< 3.0 x upper limit of normal (ULN), and total bilirubin =\\< 2.0 x ULN (or 5.0 x ULN if the participant has a history of Gilbert's disease) within 28 days prior to registration\n* Total bilirubin =\\< 2.0 x ULN (or 5.0 x ULN if the participant has a history of Gilbert's disease) within 28 days prior to registration\n* Participants must have adequate cardiac function as determined by echocardiography or MUGA scan with an ejection fraction \\>= 50% within 28 days prior to registration\n* Participants with a prior or concurrent malignancy whose natural history (in the opinion of the treating physician) does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. No concurrent therapies for such malignancy are allowed with the exception of hormonal therapy\n* Participants with known history of Wilson's disease or other known copper-metabolism disorder are excluded\n* Participants must not be pregnant or nursing. Women/men of reproductive potential must have agreed to use 2 contraception methods. A woman is considered to be of \"reproductive potential\" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods (e.g., hormonal contraceptives \\[examples include birth control pills, vaginal rings, or patches\\] associated with inhibition of ovulation for at least 1 month prior to taking study drug), \"effective contraception\" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate participant chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures. A barrier method should be used during this study along with hormonal contraceptives from initial study drug administration to 30 days after the last dose of study drug as drug-drug interaction with venetoclax is unknown\n* Participants must have agreed to have specimens submitted for translational medicine (MRD) under the myeloMATCH MSRP and specimens must be submitted\n* Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines\n* As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "59 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "overallOfficials": [
                {
                    "name": "Paul J Shami",
                    "affiliation": "SWOG Cancer Research Network",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Cedars Sinai Medical Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90048",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "310-423-8965"
                        },
                        {
                            "name": "Noah M. Merin",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "OSF Saint Joseph Medical Center",
                    "status": "RECRUITING",
                    "city": "Bloomington",
                    "state": "Illinois",
                    "zip": "61701",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "309-243-3605",
                            "email": "andersonj@illinoiscancercare.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4842,
                        "lon": -88.99369
                    }
                },
                {
                    "facility": "Illinois CancerCare-Bloomington",
                    "status": "RECRUITING",
                    "city": "Bloomington",
                    "state": "Illinois",
                    "zip": "61704",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "309-243-3605",
                            "email": "andersonj@illinoiscancercare.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4842,
                        "lon": -88.99369
                    }
                },
                {
                    "facility": "Illinois CancerCare-Canton",
                    "status": "RECRUITING",
                    "city": "Canton",
                    "state": "Illinois",
                    "zip": "61520",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "309-243-3605",
                            "email": "andersonj@illinoiscancercare.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.55809,
                        "lon": -90.03512
                    }
                },
                {
                    "facility": "Illinois CancerCare-Carthage",
                    "status": "RECRUITING",
                    "city": "Carthage",
                    "state": "Illinois",
                    "zip": "62321",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "309-243-3605",
                            "email": "andersonj@illinoiscancercare.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.91892,
                        "lon": -89.31371
                    }
                },
                {
                    "facility": "Cancer Care Specialists of Illinois - Decatur",
                    "status": "RECRUITING",
                    "city": "Decatur",
                    "state": "Illinois",
                    "zip": "62526",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "217-876-4762",
                            "email": "morganthaler.jodi@mhsil.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.84031,
                        "lon": -88.9548
                    }
                },
                {
                    "facility": "Decatur Memorial Hospital",
                    "status": "RECRUITING",
                    "city": "Decatur",
                    "state": "Illinois",
                    "zip": "62526",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "217-876-4762",
                            "email": "morganthaler.jodi@mhsil.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.84031,
                        "lon": -88.9548
                    }
                },
                {
                    "facility": "Illinois CancerCare-Dixon",
                    "status": "RECRUITING",
                    "city": "Dixon",
                    "state": "Illinois",
                    "zip": "61021",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "815-285-7800"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.83892,
                        "lon": -89.47955
                    }
                },
                {
                    "facility": "Crossroads Cancer Center",
                    "status": "RECRUITING",
                    "city": "Effingham",
                    "state": "Illinois",
                    "zip": "62401",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "217-876-4762",
                            "email": "morganthaler.jodi@mhsil.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.12004,
                        "lon": -88.54338
                    }
                },
                {
                    "facility": "Illinois CancerCare-Eureka",
                    "status": "RECRUITING",
                    "city": "Eureka",
                    "state": "Illinois",
                    "zip": "61530",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "309-243-3605",
                            "email": "andersonj@illinoiscancercare.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.72143,
                        "lon": -89.27286
                    }
                },
                {
                    "facility": "Illinois CancerCare-Galesburg",
                    "status": "RECRUITING",
                    "city": "Galesburg",
                    "state": "Illinois",
                    "zip": "61401",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "309-243-3605",
                            "email": "andersonj@illinoiscancercare.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.94782,
                        "lon": -90.37124
                    }
                },
                {
                    "facility": "Illinois CancerCare-Kewanee Clinic",
                    "status": "RECRUITING",
                    "city": "Kewanee",
                    "state": "Illinois",
                    "zip": "61443",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "309-243-3605",
                            "email": "andersonj@illinoiscancercare.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.24559,
                        "lon": -89.92483
                    }
                },
                {
                    "facility": "Illinois CancerCare-Macomb",
                    "status": "RECRUITING",
                    "city": "Macomb",
                    "state": "Illinois",
                    "zip": "61455",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "309-243-3605",
                            "email": "andersonj@illinoiscancercare.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.45921,
                        "lon": -90.6718
                    }
                },
                {
                    "facility": "Illinois CancerCare-Ottawa Clinic",
                    "status": "RECRUITING",
                    "city": "Ottawa",
                    "state": "Illinois",
                    "zip": "61350",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "309-243-3605",
                            "email": "andersonj@illinoiscancercare.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.34559,
                        "lon": -88.84258
                    }
                },
                {
                    "facility": "Illinois CancerCare-Pekin",
                    "status": "RECRUITING",
                    "city": "Pekin",
                    "state": "Illinois",
                    "zip": "61554",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "309-243-3605",
                            "email": "andersonj@illinoiscancercare.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.56754,
                        "lon": -89.64066
                    }
                },
                {
                    "facility": "Illinois CancerCare-Peoria",
                    "status": "RECRUITING",
                    "city": "Peoria",
                    "state": "Illinois",
                    "zip": "61615",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "309-243-3605",
                            "email": "andersonj@illinoiscancercare.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.69365,
                        "lon": -89.58899
                    }
                },
                {
                    "facility": "Methodist Medical Center of Illinois",
                    "status": "RECRUITING",
                    "city": "Peoria",
                    "state": "Illinois",
                    "zip": "61636",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "309-243-3605",
                            "email": "andersonj@illinoiscancercare.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.69365,
                        "lon": -89.58899
                    }
                },
                {
                    "facility": "OSF Saint Francis Medical Center",
                    "status": "RECRUITING",
                    "city": "Peoria",
                    "state": "Illinois",
                    "zip": "61637",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "309-243-3605",
                            "email": "andersonj@illinoiscancercare.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.69365,
                        "lon": -89.58899
                    }
                },
                {
                    "facility": "Illinois CancerCare-Peru",
                    "status": "RECRUITING",
                    "city": "Peru",
                    "state": "Illinois",
                    "zip": "61354",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "309-243-3605",
                            "email": "andersonj@illinoiscancercare.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.32753,
                        "lon": -89.12897
                    }
                },
                {
                    "facility": "Illinois CancerCare-Princeton",
                    "status": "RECRUITING",
                    "city": "Princeton",
                    "state": "Illinois",
                    "zip": "61356",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "309-243-3605",
                            "email": "andersonj@illinoiscancercare.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.36809,
                        "lon": -89.46481
                    }
                },
                {
                    "facility": "Southern Illinois University School of Medicine",
                    "status": "RECRUITING",
                    "city": "Springfield",
                    "state": "Illinois",
                    "zip": "62702",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "217-545-7929"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.80172,
                        "lon": -89.64371
                    }
                },
                {
                    "facility": "Memorial Medical Center",
                    "status": "RECRUITING",
                    "city": "Springfield",
                    "state": "Illinois",
                    "zip": "62781",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "217-528-7541",
                            "email": "pallante.beth@mhsil.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.80172,
                        "lon": -89.64371
                    }
                },
                {
                    "facility": "Illinois CancerCare - Washington",
                    "status": "RECRUITING",
                    "city": "Washington",
                    "state": "Illinois",
                    "zip": "61571",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "309-243-3605",
                            "email": "andersonj@illinoiscancercare.com"
                        },
                        {
                            "name": "Bryan A. Faller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.70365,
                        "lon": -89.40731
                    }
                },
                {
                    "facility": "Trinity Health Saint Joseph Mercy Hospital Ann Arbor",
                    "status": "RECRUITING",
                    "city": "Ann Arbor",
                    "state": "Michigan",
                    "zip": "48106",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "734-712-7251",
                            "email": "MCRCwebsitecontactform@stjoeshealth.org"
                        },
                        {
                            "name": "Tareq Al Baghdadi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.27756,
                        "lon": -83.74088
                    }
                },
                {
                    "facility": "Trinity Health IHA Medical Group Hematology Oncology - Brighton",
                    "status": "RECRUITING",
                    "city": "Brighton",
                    "state": "Michigan",
                    "zip": "48114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "734-712-7251",
                            "email": "MCRCwebsitecontactform@stjoeshealth.org"
                        },
                        {
                            "name": "Tareq Al Baghdadi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.52948,
                        "lon": -83.78022
                    }
                },
                {
                    "facility": "Trinity Health IHA Medical Group Hematology Oncology - Canton",
                    "status": "RECRUITING",
                    "city": "Canton",
                    "state": "Michigan",
                    "zip": "48188",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "734-712-7251",
                            "email": "MCRCwebsitecontactform@stjoeshealth.org"
                        },
                        {
                            "name": "Tareq Al Baghdadi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.30865,
                        "lon": -83.48216
                    }
                },
                {
                    "facility": "Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital",
                    "status": "RECRUITING",
                    "city": "Chelsea",
                    "state": "Michigan",
                    "zip": "48118",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "734-712-7251",
                            "email": "MCRCwebsitecontactform@stjoeshealth.org"
                        },
                        {
                            "name": "Tareq Al Baghdadi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.31807,
                        "lon": -84.02181
                    }
                },
                {
                    "facility": "Genesee Cancer and Blood Disease Treatment Center",
                    "status": "RECRUITING",
                    "city": "Flint",
                    "state": "Michigan",
                    "zip": "48503",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "810-762-8038",
                            "email": "wstrong@ghci.org"
                        },
                        {
                            "name": "Tareq Al Baghdadi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.01253,
                        "lon": -83.68746
                    }
                },
                {
                    "facility": "Genesee Hematology Oncology PC",
                    "status": "RECRUITING",
                    "city": "Flint",
                    "state": "Michigan",
                    "zip": "48503",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "810-762-8038",
                            "email": "wstrong@ghci.org"
                        },
                        {
                            "name": "Tareq Al Baghdadi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.01253,
                        "lon": -83.68746
                    }
                },
                {
                    "facility": "Genesys Hurley Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Flint",
                    "state": "Michigan",
                    "zip": "48503",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "810-762-8038",
                            "email": "wstrong@ghci.org"
                        },
                        {
                            "name": "Tareq Al Baghdadi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.01253,
                        "lon": -83.68746
                    }
                },
                {
                    "facility": "Hurley Medical Center",
                    "status": "RECRUITING",
                    "city": "Flint",
                    "state": "Michigan",
                    "zip": "48503",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "810-762-8038",
                            "email": "wstrong@ghci.org"
                        },
                        {
                            "name": "Tareq Al Baghdadi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.01253,
                        "lon": -83.68746
                    }
                },
                {
                    "facility": "Trinity Health Saint Mary Mercy Livonia Hospital",
                    "status": "RECRUITING",
                    "city": "Livonia",
                    "state": "Michigan",
                    "zip": "48154",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "734-712-7251",
                            "email": "MCRCwebsitecontactform@stjoeshealth.org"
                        },
                        {
                            "name": "Tareq Al Baghdadi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.36837,
                        "lon": -83.35271
                    }
                },
                {
                    "facility": "Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus",
                    "status": "RECRUITING",
                    "city": "Ypsilanti",
                    "state": "Michigan",
                    "zip": "48197",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "734-712-7251",
                            "email": "MCRCwebsitecontactform@stjoeshealth.org"
                        },
                        {
                            "name": "Tareq Al Baghdadi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.24115,
                        "lon": -83.61299
                    }
                },
                {
                    "facility": "Baptist Memorial Hospital and Cancer Center-Golden Triangle",
                    "status": "RECRUITING",
                    "city": "Columbus",
                    "state": "Mississippi",
                    "zip": "39705",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "901-226-1366",
                            "email": "BCCclintrials@bmhcc.org"
                        },
                        {
                            "name": "Salil Goorha",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.49567,
                        "lon": -88.42726
                    }
                },
                {
                    "facility": "Baptist Cancer Center-Grenada",
                    "status": "RECRUITING",
                    "city": "Grenada",
                    "state": "Mississippi",
                    "zip": "38901",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "901-226-1366",
                            "email": "BCCclintrials@bmhcc.org"
                        },
                        {
                            "name": "Salil Goorha",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.769,
                        "lon": -89.80842
                    }
                },
                {
                    "facility": "Baptist Memorial Hospital and Cancer Center-Union County",
                    "status": "RECRUITING",
                    "city": "New Albany",
                    "state": "Mississippi",
                    "zip": "38652",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "901-226-1366",
                            "email": "BCCclintrials@bmhcc.org"
                        },
                        {
                            "name": "Salil Goorha",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.49427,
                        "lon": -89.00784
                    }
                },
                {
                    "facility": "Baptist Memorial Hospital and Cancer Center-Oxford",
                    "status": "RECRUITING",
                    "city": "Oxford",
                    "state": "Mississippi",
                    "zip": "38655",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "901-226-1366",
                            "email": "BCCclintrials@bmhcc.org"
                        },
                        {
                            "name": "Salil Goorha",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.3665,
                        "lon": -89.51925
                    }
                },
                {
                    "facility": "Baptist Memorial Hospital and Cancer Center-Desoto",
                    "status": "RECRUITING",
                    "city": "Southhaven",
                    "state": "Mississippi",
                    "zip": "38671",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "901-226-1366",
                            "email": "BCCclintrials@bmhcc.org"
                        },
                        {
                            "name": "Salil Goorha",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.99176,
                        "lon": -90.12759
                    }
                },
                {
                    "facility": "Siteman Cancer Center at West County Hospital",
                    "status": "RECRUITING",
                    "city": "Creve Coeur",
                    "state": "Missouri",
                    "zip": "63141",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "800-600-3606",
                            "email": "info@siteman.wustl.edu"
                        },
                        {
                            "name": "Ramzi Abboud",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.66089,
                        "lon": -90.42262
                    }
                },
                {
                    "facility": "Washington University School of Medicine",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "800-600-3606",
                            "email": "info@siteman.wustl.edu"
                        },
                        {
                            "name": "Ramzi Abboud",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Siteman Cancer Center-South County",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63129",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "800-600-3606",
                            "email": "info@siteman.wustl.edu"
                        },
                        {
                            "name": "Ramzi Abboud",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Siteman Cancer Center at Christian Hospital",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63136",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "800-600-3606",
                            "email": "info@siteman.wustl.edu"
                        },
                        {
                            "name": "Ramzi Abboud",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Siteman Cancer Center at Saint Peters Hospital",
                    "status": "RECRUITING",
                    "city": "Saint Peters",
                    "state": "Missouri",
                    "zip": "63376",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "800-600-3606",
                            "email": "info@siteman.wustl.edu"
                        },
                        {
                            "name": "Ramzi Abboud",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.80033,
                        "lon": -90.62651
                    }
                },
                {
                    "facility": "Baptist Memorial Hospital and Cancer Center-Collierville",
                    "status": "RECRUITING",
                    "city": "Collierville",
                    "state": "Tennessee",
                    "zip": "38017",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "901-226-1366",
                            "email": "BCCclintrials@bmhcc.org"
                        },
                        {
                            "name": "Salil Goorha",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.04204,
                        "lon": -89.66453
                    }
                },
                {
                    "facility": "Baptist Memorial Hospital and Cancer Center-Memphis",
                    "status": "RECRUITING",
                    "city": "Memphis",
                    "state": "Tennessee",
                    "zip": "38120",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "901-226-1366",
                            "email": "BCCclintrials@bmhcc.org"
                        },
                        {
                            "name": "Salil Goorha",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.14953,
                        "lon": -90.04898
                    }
                },
                {
                    "facility": "Centro Comprensivo de Cancer de UPR",
                    "status": "RECRUITING",
                    "city": "San Juan",
                    "zip": "00927",
                    "country": "Puerto Rico",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "888-823-5923",
                            "email": "ctsucontact@westat.com"
                        },
                        {
                            "name": "Luis J. Santos Reyes",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 18.46633,
                        "lon": -66.10572
                    }
                },
                {
                    "facility": "San Juan City Hospital",
                    "status": "RECRUITING",
                    "city": "San Juan",
                    "zip": "00936",
                    "country": "Puerto Rico",
                    "contacts": [
                        {
                            "name": "Site Public Contact",
                            "role": "CONTACT",
                            "phone": "787-763-1296"
                        },
                        {
                            "name": "Luis J. Santos Reyes",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 18.46633,
                        "lon": -66.10572
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.",
            "url": "https://grants.nih.gov/policy/sharing.htm"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000007951",
                    "term": "Leukemia, Myeloid"
                },
                {
                    "id": "D000015470",
                    "term": "Leukemia, Myeloid, Acute"
                },
                {
                    "id": "D000009196",
                    "term": "Myeloproliferative Disorders"
                },
                {
                    "id": "D000054437",
                    "term": "Myelodysplastic-Myeloproliferative Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12149",
                    "name": "Myeloproliferative Disorders",
                    "asFound": "Myeloproliferative Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10955",
                    "name": "Leukemia, Myeloid",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18127",
                    "name": "Leukemia, Myeloid, Acute",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14164",
                    "name": "Preleukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M12145",
                    "name": "Myelodysplastic Syndromes",
                    "relevance": "LOW"
                },
                {
                    "id": "M27707",
                    "name": "Myelodysplastic-Myeloproliferative Diseases",
                    "asFound": "Myelodysplastic/Myeloproliferative Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T1311",
                    "name": "Chronic Myeloproliferative Disorders",
                    "asFound": "Myeloproliferative Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3994",
                    "name": "Myelodysplastic/myeloproliferative Disease",
                    "asFound": "Myelodysplastic/Myeloproliferative Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3995",
                    "name": "Myeloid Leukemia",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T182",
                    "name": "Acute Myeloid Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T188",
                    "name": "Acute Non Lymphoblastic Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3993",
                    "name": "Myelodysplastic Syndromes",
                    "relevance": "LOW"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003561",
                    "term": "Cytarabine"
                },
                {
                    "id": "D000001374",
                    "term": "Azacitidine"
                },
                {
                    "id": "C000579720",
                    "term": "Venetoclax"
                },
                {
                    "id": "D000003630",
                    "term": "Daunorubicin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000000903",
                    "term": "Antibiotics, Antineoplastic"
                },
                {
                    "id": "D000059005",
                    "term": "Topoisomerase II Inhibitors"
                },
                {
                    "id": "D000059003",
                    "term": "Topoisomerase Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M249656",
                    "name": "Venetoclax",
                    "asFound": "Etc.",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4673",
                    "name": "Azacitidine",
                    "asFound": "Pilot Study",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6766",
                    "name": "Cytarabine",
                    "asFound": "Delivered",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6832",
                    "name": "Daunorubicin",
                    "asFound": "Marrow",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6263",
                    "name": "Coal Tar",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "relevance": "LOW"
                },
                {
                    "id": "M29348",
                    "name": "Topoisomerase Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "Derm",
                    "name": "Dermatologic Agents"
                }
            ]
        }
    },
    "hasResults": false
}